Ph 3 STELLAR clinical study results showing clinically meaningful benefits with eflornithine + lomustine in patients with grade 3 astrocytoma
“For 30 years, SNO has been at the forefront of neuro-oncology, driving discovery and improving patient care, which is why we are excited to have these encouraging results from the STELLAR Study presented at this meeting,” said Jason Levin, President and Chief Executive Officer at Orbus. “In patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma, eflornithine not only improved overall survival but, as determined by a blinded independent central review, improved progression-free survival as well. I believe these data, while taken from a subset analysis, represent one of the first meaningful advances for a patient population in which outcomes have been poor for years.”
Share:
More News
“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.
“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to
“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the
“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the